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Does the thoroughly old-fashioned technique of passive immunisation have anything to offer when we are challenged by a novel, potentially lethal infection such as severe acute respiratory syndrome (SARS)? It is over 100 years since antibodies in convalescent serum were first used for this purpose. The intervening decades have seen innovations such as hybridomas to make monoclonal antibodies, plus Greg Winter's work in Cambridge on single domain antibodies (DAbs). Time, perhaps, to dust down the ancient concept and see whether it might be applied with the benefit of modern technology.
One occasion when passive immunisation was used successfully in its traditional guise was the Lassa fever epidemic in Nigeria in 1969. Virologist Wilbur Downs got the idea from his colleague Karl Johnson, who had tackled a similar crisis in Panama-an outbreak of Bolivian haemorrhagic fever caused by Machupo virusby administering immune serum from patients who had recovered from the disease.
John Fuller describes vividly in his book Fever (Reader's Digest Press, 1974) Downs' dilemma of whether to transfuse serum, taken from a woman who had partly recovered from Lassa fever, into a terribly ill man suspected of having the disease. What about the risks of serum transfusion such as the possibility of triggering anaphylactic shock and the chance of inadvertently transferring hepatitis B virus? What if the precious serum was wasted because the man did not have Lassa fever at all? Conversely, was there a danger of giving him the disease if virus particles had persisted in the woman's bloodstream? If he really did have Lassa fever, would passive immunisation interfere with the development of his own, potentially beneficial, immune response? In the event, and after much heart-searching, Downs and his colleagues decided to transfuse the serum. They were lucky: it worked.
Lassa fever was, of course, a special case. Its agent was a highly virulent "hot" virus, whose unusually lethal potential justified extreme measures. But SARS too can be deadly-and is just as invulnerable to antivirals and antibiotics. Moreover, a conventional vaccine is years away.
By contrast, DAbs can be generated in days-by immunising animals against a particular antigen, using PCR to clone the genes encoding antibody specificities (rearranged immunoglobulin heavy chain variable genes) directly into vectors for expression in Escherichia coli, and then screening the bacterial colonies for antigen-binding activities. Faced with SARS or something like it, could we now clone the relevant genes from a convalescent patient's spleen cells (or indeed lymphocytes in peripheral blood) and splice them into E coli as a workhorse for immunoglobulin production?
The idea would not work if the coronavirus thought to be responsible for SARS proves to be antigenically changeable. True, the organism has come to human attention because it is a novel product of mutation or recombination. But that does not necessarily mean that it will alter its spots in future so significantly and/or frequently that passive immunisation would be pointless. The same argument applies, of course, to conventional vaccination.
A condition for which passive immunisation with monoclonals is being urgently investigated is anthrax. Although the organism is sensitive to antibiotics, these can fail to prevent disease and death because the "lethal" and "oedema" toxins continue to cause damage. Maybe potent monoclonals are the answer.
Although the Chinese authorities were woefully slow in alerting the rest of the world to the problem of SARS, scientific progress in characterising the infection has been astonishingly rapid. The WHO issued its first alert on March 12. The suspected coronavirus was described 8 days later. A detailed paper on the condition and the organism appeared in the online edition of The Lancet on April 8. And the British Columbia Cancer Research Centre in Vancouver, Canada, released its complete genome data on April 12. An impressive month's work.
Over a much longer timescale-since the early 1900s, when plasma from vaccinated horses was first used for anthrax treatment-there have been momentous developments in immunology. Is it time to apply that knowledge to villains such as SARS?
